Compare Las Vegas Sands Corp. (LVS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs Recursion Pharmaceuticals Inc — how do they compare? Las Vegas Sands Corp. trades at $36.42 (market cap $23.38B), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.14B). The key difference: Las Vegas Sands Corp. is far larger — about 10.9× Recursion Pharmaceuticals Inc's market cap, and Las Vegas Sands Corp. pays a 3.32% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Las Vegas Sands Corp. for 72 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| LVS | RXRX | |
|---|---|---|
Market Cap | $23.38B | $2.14B |
Volume | 6,994,661 | 30,789,535 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $6.79 |
52-Week Low | $35.81 | $2.84 |
Typical Hold Time | 72 Days | 22 Days |
Enterprise Value | $35.27B | $1.66B |
Dividend Yield | 3.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $35.81, down 1.38% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported revenue of $13.02B in 2025 with a net income margin of 12.59%, and recent earnings show mixed results with a Q2 2026 miss. Analysts maintain a strong buy consensus with a $59.78 price target, indicating significant upside potential from current levels.
The outlook for LVS is positive based on solid fundamentals and analyst optimism, but risks include high debt levels and reliance on Macao's tourism sector. Near-term performance may hinge on Q3 2026 earnings and ongoing stock repurchases, while long-term growth is supported by non-gaming expansions and community initiatives in Macao.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
